- S&P 5002,775.60+1.09%
- Dow 3025,883.25+1.74%
- Nasdaq7,472.41+0.61%
- Russell 20001,569.25+1.56%
- Crude Oil55.79+2.54%
- Gold1,325.00+0.84%
- Silver15.76+1.46%
- EUR/USD1.1297-0.0113%
- 10-Yr Bond2.6660+0.34%
- Vix14.91-8.08%
- GBP/USD1.2897+0.7777%
- USD/JPY110.5350+0.0262%
- BTC-USD3,612.46+0.52%
- FTSE 1007,236.68+0.55%
- Nikkei 22520,900.63-1.13%
Most Removed from Watchlists
1.15k followers • 29 symbols Watchlist by Yahoo Finance
Follow this list to discover and track stocks that were removed from most watchlists by Yahoo Finance Users. This list is generated daily and limited to the top 30 stocks that meet the criteria.
29 Symbols
Get the Yahoo Finance app
- Free real-time data
- News and price alerts
- Add and edit holdings
- Track performance
- Create multiple watchlists
- Reuters•9 hours ago
U.S. Medicare plans to track CAR-T cancer therapy outcomes
The U.S. Centers for Medicare & Medicaid Services (CMS) on Friday proposed coverage of expensive CAR-T cell therapies at cancer centers that meet criteria including a registry or clinical study to monitor how well patients fare for at least two years after treatment. New hospital payment terms from Medicare, the federal government healthcare program for the elderly and disabled, are expected later in the year. If the proposal is finalized, use of CAR-Ts for Medicare patients could continue to be limited to the largest regional cancer centers.
- Moody's•10 hours ago
Eli Lilly and Company -- Moody's announces completion of a periodic review of ratings of Eli Lilly and Company
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Eli Lilly and Company and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
- Moody's•10 hours ago
Gilead Sciences, Inc. -- Moody's announces completion of a periodic review of ratings of Gilead Sciences, Inc.
Announcement: Moody's announces completion of a periodic review of ratings of Gilead Sciences, Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Gilead Sciences, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- MarketWatch•12 hours ago
Medicare would cover CAR-T therapies under new CMS proposal
Under a new proposal by the Centers for Medicare & Medicaid Services, the Medicare program would cover FDA-approved CAR-T therapies. CAR-T, or chimeric anitgen receptor T-cell, therapies use genetically-engineered immune cells called T cells to more specifically target cancer cells. CMS said the proposal, announced Friday, would require Medicare to cover the cancer treatment when it is offered in a CMS-approved registry or clinical study, as long as data is collected from the patients for at least two years after treatment. CMS said it plans to use the information to decide what treatments are most beneficial to patients and which CAR-T therapies to fund in the future. "Today's proposed coverage decision would improve access to this therapy while deepening CMS's understanding of how patients in Medicare respond to it, so the agency can ensure that it is paying for CAR T-cell therapy for cases in which the benefits outweigh the risks," said CMS Administrator Seema Varma in a statement. There are currently only two approved CAR-T therapies in the U.S., and both are very expensive. Novartis's Kymriah has a list price of $475,000, while and Gilead Sciences Inc.'s Yescarta is priced at $373,000. There is no national Medicare policy for covering the expensive new cancer treatment, so it is currently up to local Medicare administrative contractors to decide whether to pay for it. Shares of Novartis have gained 4.3% in the year to date, while shares of Gilead have gained 6.3%. The SPDR S&P Pharmaceuticals ETF has gained 13.5% and the S&P 500 has gained 10.4%.
- Reuters•14 hours ago
Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
German drugmaker Bayer took full control of Vitrakvi, a drug used against a variety of cancers driven by a rare genetic mutation, in a deal with from Eli Lilly's Loxo Oncology. Bayer said on Friday it exercised a right to gain exclusive licensing rights for the global development and commercialization of Vitrakvi, also known as larotrectinib, under a clause in the initial collaboration deal with Loxo Oncology that provided for Loxo becoming a takeover target.
- Motley Fool•16 hours ago
Why TripAdvisor and Activision Blizzard Have Investors So Skittish
One rose on earnings and one fell, but neither is looking all that attractive in the near term.
- Motley Fool•16 hours ago
Why TripAdvisor Investors Have Reservations
The company’s mixed quarterly results sent shares sliding Wednesday.
- Zacks•16 hours ago
Amazon (AMZN) Abandons Headquarter Plans in NY Amid Protests
Amazon (AMZN) abruptly drops its HQ2 proposal in New York City after facing a month of city council grilling and objections raised by the locals, politicians and activists.
- Zacks•16 hours ago
Goldcorp's (GG) Q4 Earnings Beat, Sales Trail Estimates
Goldcorp's (GG) Q4 results gain from lower costs amid declining production. For 2019, it expects to produce 2.2-2.4 million ounces of gold at AISC of $750-$850 per ounce.
- Market Realist•18 hours ago
What Analysts Are Suggesting for Procter & Gamble Stock
Will Procter & Gamble Sustain Momentum in the Second Half?(Continued from Prior Part)Analysts have raised their target prices Procter & Gamble (PG) has reported strong a fiscal 2019 first-half performance, following which several analysts
- Motley Fool•yesterday
Ellie Mae's Slowdown Makes Selling Out Look Smart
The mortgage software company continued to see its growth decelerate.
- Market Realist•yesterday
Will Cost Headwinds Limit Procter & Gamble’s EPS Growth?
Will Procter & Gamble Sustain Momentum in the Second Half?(Continued from Prior Part)Strong past performance Procter & Gamble (PG) has an impressive history of beating Wall Street’s estimates even amid heightened cost pressures. Procter
- Investor's Business Daily•yesterday
Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst
An RBC Capital Markets analyst is "head over heels" for five biotech stocks, two with high Relative Strength Ratings. In afternoon action in the stock market, biotech stocks inched up.
Market Realist•yesterdayWill Procter & Gamble’s Organic Sales Continue to Improve?
Will Procter & Gamble Sustain Momentum in the Second Half?(Continued from Prior Part)Higher pricing to drive organic salesWe expect Procter & Gamble (PG) to sustain the momentum in its organic sales, reflecting higher pricing across all its
- GuruFocus.com•yesterday
Goldcorp Posts 4th-Quarter Results
Shares of Goldcorp Inc. (GG) rose 0.28% to $10.8 in after-hours trading Wednesday after the company posted fourth-quarter and full-year 2018 results. The miner closed the quarter with non-GAAP earnings of 7 cents per share, topping consensus estimates by 4 cents. Earnings declined 50% from the prior-year quarter.
- Market Realist•yesterday
Will Procter & Gamble Sustain Momentum in the Second Half?
Will Procter & Gamble Sustain Momentum in the Second Half?Strength in underlying business likely to sustainProcter & Gamble (PG) has impressed with its financial performance in the first half of fiscal 2019 thanks to improved underlying
- Zacks•2 days ago
Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings
Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.
- Motley Fool•2 days ago
How Solid Is Ellie Mae's Sale to Thoma Bravo?
The private equity firm is offering $3.7 billion for the mortgage industry software provider, but what if another suitor appears?
- Motley Fool•2 days ago
3 Important Trends in TripAdvisor's 2018 Rebound
It was a good year for the travel booking giant's business even though sales growth decelerated.
- InvestorPlace•2 days ago
Should You Buy Viking Therapeutics After Gilead Drug Failure?
Shares of Viking Therapeutics (NASDAQ:VKTX) are making headlines this week after an announcement from Gilead Sciences (NASDAQ:GILD), that one of its drugs did not meet the primary endpoints of its Phase 3 clinical trial. This gave a possible opening to Viking Therapeutics, which gave a boost to VKTX stock.Source: Shutterstock Does that make it a buy? Let's examine the stock a bit more closely. If you haven't heard of VKTX stock before, don't feel guilty. With a market cap of just $650 million, it's not a well-known company. It's not a Bristol-Myers Squibb (NYSE:BMY), Celgene (NASDAQ:CELG), Biogen (NASDAQ:BIIB) or another large cap biotech company. Breaking Down VKTX StockViking Therapeutics is a self-described "clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders." The company is working on several treatments, one of which includes enrolling VK2809, which is aimed at fatty liver and hypercholesterolemia, in a Phase 2 study. Gilead's Selonsertib liver treatment failed its Phase 3 clinical trial earlier this week, thus giving some hope to VKTX stock.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 9 U.S. Stocks That Are Coming to Life Again The company also has VK5211, "an orally available, non-steroidal SARM designed to selectively stimulate muscle and bone formation."At the end of the day, Viking Therapeutics has some intriguing developments in its pipeline. But at the same time, this is also a speculative biotech company. Investors are, to some degree, betting on a binary event. Either VKTX stock is a multi-bagger with big-time potential if it gains regulatory approval and/or is acquired by a larger company, or neither of those things happen and it's a total dud. That's the nature of the beast with young biotech stocks.Case in point? Viking Therapeutics stock doesn't have any revenue. Its pipeline is promising, but that's all investors are betting on at this point. There's no real way to evaluate the business because there is no business! At least in the traditional sense. VKTX has enough money in the bank to fund its operations for the time being, but its future hinges solely on its treatments. Trading VKTX StockHopefully the chart above doesn't seem too complex. I only wanted to lay out a few different levels and prior trends that played a role in VKTX stock over the last 12 months.Like most of the market, VKTX came into Q4 near its highs, although admittedly under some pressure already. Still, the stock was pummeled along with the S&P 500 and other major market indices as Q4 got under way. VKTX stock price bottomed near $7 on Christmas Eve and has been working higher since.VKTX stock is now over the 50-day and 21-day moving averages. For traders and investors that are going in on this, perhaps consider using a $7 as a key reference level. Below this mark and Viking Therapeutics stock could be in trouble.As much as I want to say that the stock is okay over uptrend support (purple line) and moving average support -- and really, it is -- know that this is a speculative position that is subject to extreme moves in both directions. These moves can appear overnight and there's little investors can do about it other than planning ahead with proper position sizing. * Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks? For those that don't want such a speculative position, consider choosing between two companies like Celgene and Gilead.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 U.S. Stocks That Are Coming to Life Again * The 7 Best Video Game Stocks to Power Up Your Portfolio! * 5 Tips to Become a Better Stock Trader Compare Brokers The post Should You Buy Viking Therapeutics After Gilead Drug Failure? appeared first on InvestorPlace.
- Zacks•2 days ago
Ellie Mae (ELLI) Lags Q4 Earnings Estimates
Ellie Mae (ELLI) delivered earnings and revenue surprises of -25.00% and 1.82%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Zacks•2 days ago
TripAdvisor (TRIP) Lags Q4 Earnings Estimates, Tops Revenues
TripAdvisor (TRIP) reports mixed fourth-quarter results. The non-hotel business performs well in the quarter. However, competition remains a major concern.
- American City Business Journals•2 days ago
Encana closes multibillion-dollar acquisition of Woodlands co.
Two Newfield directors have joined Encana's board, and Encana plans to proceed with its previously announced increases to its dividend and share buyback program.
